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Brief Definitive Report

Register shifting of an insulin peptide–MHC
complex allows diabetogenic T cells
to escape thymic deletion

The Journal of Experimental Medicine

Department of Pathology and Immunology, School of Medicine, Washington University in St. Louis, St. Louis, MO 63110

In nonobese diabetic (NOD) mice, two sets of autoreactive CD4+ T cells recognize the B:9–
23 segment of the insulin B chain. One set, type A, recognizes insulin presented by antigenpresenting cells (APCs). These T cells are highly deleted in the thymus. The second set,
type B, does not recognize insulin protein but reacts with soluble B chain peptide. This set
is not deleted in the thymus but is activated in the islets of Langerhans. In this study, we
examine the specificity of these two types of T cells. The protein-reactive set recognizes
the stretch of residues 13–21 of the insulin B chain. The set reactive to peptide only
recognizes the stretch from residues 12–20. A single amino acid shift of the B chain peptide bound to I-Ag7 determines whether T cells recognize peptides generated by the processing of insulin, and consequently their escape from thymic purging. Biochemical experiments
indicate that peptides bound in the 13–21 register interact more favorably with I-Ag7 than
peptides that bind in the 12–20 register. Thus, self-reactive T cells can become pathogenic
in the target organ where high concentrations of antigen and/or differences in intracellular
processing present peptides in registers distinct from those found in the thymus.
CORRESPONDENCE
Emil R. Unanue:
Unanue@wustl.edu
Abbreviations used: HEL, hen egg
white lysozyme; NOD, nonobese
diabetic; pMHC, peptide–MHC.

A central issue in the study of autoimmunity concerns the nature of the autologous peptides recognized by the autoreactive T cells: do certain
self peptides bound to MHC molecules have distinctive features that allow for the activation of
autoreactive T cells? Issues of binding affinity,
posttranslational modifications, conformational
isomers, and register shifting of self peptides
have all been the subject of analysis by many
laboratories (Liu et al., 1995; Anderton, 2004;
Bankovich et al., 2004; Lovitch and Unanue,
2005; Goverman, 2009). Solutions to these various issues could potentially explain why selfreactive T cells escape thymic selection and
subsequently become pathogenic in the target
tissue. Our own interest centers on whether the
peptide–MHC (pMHC) complex presented by
tissue APCs may be distinct compared with
the pMHC being presented, if at all, by thymic
APCs during T cell selection.
In the nonobese diabetic (NOD) mouse, the
islet autoimmune response is highly focused
against the insulin molecule. The insulin autoreactivity is a major contributing factor and is essential for the development of diabetes (Daniel
et al., 1995; French et al., 1997; Jaeckel et al.,
2004; Nakayama et al., 2005, 2007). A recent
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study of ours analyzing the T cell response
during diabetogenesis of NOD mice led to the
identification of a notable set of autoreactive
CD4+ T cells that recognized insulin peptides
found in the early islet infiltrates of NOD mice
(Mohan et al., 2010). These CD4+ T cells recognized the 9–23 residue stretch of the insulin B
chain (B:9–23), a peptide which binds to I-Ag7 at
very low affinity with a fast rate of dissociation
(Yu et al., 2000; Levisetti et al., 2007). Importantly, most of the anti-insulin T cells did not recognize the B:9–23 segment when the insulin
protein was processed by the APCs; these T cells
only recognized the B:9–23 segment when it was
offered as an exogenous peptide. In brief, we iden
tified subsets of T cells against an insulin epitope
that exhibited a pattern of reactivity akin to
T cells identified when studying the protein hen
egg white lysozyme (HEL), which we had termed
type A and B (Lovitch and Unanue, 2005).
These insulin peptide–specific T cells were
readily activated by APCs normally inhabiting
the islets of Langerhans (Calderon et al., 2008)
© 2011 Mohan et al. This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months after the
publication date (see http://www.rupress.org/terms). After six months it is available
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RESULTS AND DISCUSSION
Insulin-reactive type A and B T cells recognize different
registers of the B:9–23 peptide
Previously, a cohort of insulin-reactive CD4+ T cell hybridomas was generated from the infiltrated islets of prediabetic

NOD mice or by immunization with the insulin B chain
peptide encompassing residues 9–23. These B:9–23-reactive
T cell hybridomas were divided into two groups based on
their ability to recognize the insulin protein processed by
APCs in standard T cell assays. Those that recognized both
insulin and B:9–23 peptide presented by APCs were called
type A T cells, whereas those only recognizing the B:9–23
peptide but not the insulin molecule were called type B
(Mohan et al., 2010). In this study, the ability of these T cells
to recognize mouse preproinsulin proteins was tested in two
experimental systems: in one, the C3.G7 APC line was cultured with recombinant mouse preproinsulin I or II, and in
the other manipulation, the same APC was engineered to
endogenously express mouse preproinsulin I or II via retroviral
transduction of their respective cDNA.
Both type A and B T cells were activated by adding the
B:9–23 peptide to the C3.G7 APC line (Fig. 1 a). The type A
T cells recognized recombinant mouse preproinsulin I and II
when added to the APC (Fig. 1 a) or to either of the proteins
expressed in the C3.G7 line (Fig. 1 b). Type B T cells were
incapable of recognizing preproinsulin in either situation
(Fig. 1, a and b). Collectively, these results confirmed our previous findings using exogenous human insulin (Mohan et al.,
2010): the type B T cells did not recognize the B:9–23 epi
tope generated by the processing of mouse insulin proteins.
A previous study in the laboratory indicated that T cells
reacted only to two partially overlapping nine amino acid

Figure 1. Type A and B reactive T cells recognize distinct registers of the B:9–23 peptide. (a) IL-2 production by T cell hybridomas in response to
B:9–23 peptide, mouse preproinsulin I, or mouse preproinsulin II, presented by the C3.G7 APC cell line. (b) IL-2 production in response to C3.G7 cells expressing mouse preproinsulin I and preproinsulin II cDNA constructs. (c and d) Response of two type A hybridomas (4F7 and IIT-3; c) and two type B hybridomas (8F10 and 2D10; d) to the B:12–20 (register 1) and B:13–21 (register 2) peptides covalently linked to I-Ag7 expressed on C3.G7 cells. (e) Response
of type A and type B hybridomas to the B:14–23 peptide linked to I-Ag7 (register 3) expressed on M12.C3 cells. Error bars indicate SEM. Data are representative of three independent experiments.
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but not by any other tissue APCs, including those in the thymus.
Importantly, the secretory granules from  cells, in addition to
containing the high amounts of mature insulin molecules, also
contained peptide fragments derived from the insulin protein.
These granules were taken up by the intraislet APCs and
charged their MHC molecules with insulin-derived peptides,
explaining the activation of these peptide-specific T cells. Such
peptide-specific T cell lines transferred into nondiabetic NOD
mice were specifically recruited to the islets and caused diabetes
(Mohan et al., 2010). The fact that these peptide-specific T cells
are not clonally deleted in the thymus, even though they are
pathogenic, unmistakably underscores their importance.
In this study, we examine and explain the features of the
CD4+ type A and B T cells against the B chain of insulin. The
explanation for their dissimilar reactivity lies in the peptide segment being recognized: type A T cells recognized the B:13–21
register bound to I-Ag7, whereas type B T cells recognized the
B:12–20 register. A single residue shift of the peptide segment
bound within the binding groove of the MHC distinguished
both sets of autoreactive T cells. An explanation for such distinction lies in the binding properties of each segment.

Br ief Definitive Repor t

The B21 glutamic acid influences register selection
of covalent pMHC
In our previous study (Mohan et al., 2010), only the type A
T cells but not the type B T cells recognized the covalent
linkage of the entire B:9–23 peptide to I-Ag7. This indicated
that the linked B:9–23 peptide was solely bound in register
2:13–21. To address this issue, a panel of truncated B:9–23
peptides covalently linked to the I-Ag7 molecule was developed to determine which residues influenced register binding.
Peptides with various lengths of the N-terminal flank were all
JEM Vol. 208, No. 12

recognized by type A T cells but not by type B T cells (Fig. 2 a).
Thus, regardless of the N-terminal flank length, the covalently
bound peptide was always presented in register 2:13–21.
Next, covalent complexes with truncations of the
C-terminal residues were examined. A cell line with truncation
of two amino acids at the C terminus of the peptide (C3.
G7B:9–21) was only recognized by type A T cells and not by
type B T cells (Fig. 2 b). Pointedly, when the C terminus was
further truncated by removing the B21 glutamic acid to generate the C3.G7B:9–20 cell line, the opposite outcome was
observed. The G7B:9–20 complex was recognized by type B
T cells but not by the type A T cells (Fig. 2 b).
These results suggest that the glutamic acid at position
21 in the covalently linked pMHC locks register 2 in the
peptide-containing groove of I-Ag7 molecules; register 1 is
only presented when this residue is absent in the covalently
linked complexes. Therefore, we surmised that the addition
of a single amino acid, the B21 glutamic acid, to the B:12–20
peptide should shift the presentation from register 1:12–20 to
register 2:13–21. Accordingly, a covalent cell line expressing
B:12–21 (VEALYLVCGE), which contains the minimal
peptide encompassing the two registers, was only recognized
by type A T cells and not by type B T cells (Fig. 2 c).

Figure 2. The glutamic acid at B21 determines register binding of
covalently linked insulin pMHC molecules. (a) Response of type A (IIT-3)
and type B (8F10) hybridomas to N-terminal truncated variants of the
B:9–23 peptide covalently linked to I-Ag7 expressed on M12.C3 cells.
(b) Type A (IIT-3) and type B (8F10) T cell response to cells expressing covalently linked B:9–20 and B:9–21 C-terminal truncations of B:9–23.
(c) Type A (IIT-3) and type B (8F10) T cell response to the G7B:12–21 cell
line. Error bars indicate SEM. Data are representative of three independent experiments.
2377
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registers within the B:9–23 peptide, (SHLVEALYLVCGERG;
Levisetti et al., 2007): register 1 encompassing the 12–20
(VEALYLVCG) segment and register 2 using the 13–21
(EALYLVCGE) segment (the P9 residue of each is underlined). To test whether type A or B T cells were restricted to
one of the two registers of the peptide bound to the I-Ag7
MHC molecule, APCs were generated containing the minimal registers covalently bound to the I-Ag7  chain via a flexible glycine/serine linker (Kozono et al., 1994; Landais et al.,
2009). These constructs, along with the I-Ag7  chain were
expressed in the M12.C3 B lymphoma cell line. All cell lines
used in these experiments expressed comparable levels of
I-Ag7 on the cell surface (not depicted).
Constructs containing either register 1 or register 2 segments covalently bound to the I-Ag7  chain were generated
and expressed in the M12.C3 cell line. The cell line expressing the register 2:13–21 segment covalently linked to I-Ag7
(C3.G7B:13–21) was exclusively recognized by the type A
T cells but not by the type B T cells (Fig. 1, c and d). We
found no examples of a type B T cell activated by the register
2:13–21 complex. In striking contrast, the type B T cells recognized the register 1:12–20 segment covalently linked to
I-Ag7 (C3.G7B:12–20; Fig. 1, c and d). Whereas the majority
of type A T cells only recognized the C3.G7B:13–21 cell
line, interestingly, a subset of them also recognized register
1:12–20 covalently linked to I-Ag7 (Fig. 1 c).
A third potential binding register previously suggested to
encompass the B:14–22 segment (register 3:14–22) of the peptide (Stadinski et al., 2010) was evaluated. A cell line expressing
the B:14–23 segment covalently linked to I-Ag7 (C3.G7B:
14–23) did not stimulate any type A or B hybridomas (Fig. 1 e).
Although no type B T cells recognized register 2, a subset
of type A T cells recognized both registers 1 and 2 covalently
bound; note in Table S1 their incidence to presentation by C3.
G7B:12–20 and to C3.G7B:9–20. Further studies are needed to
examine their specificity; such a group may recognize the 13–20
segment plus the adjacent glycine from the linker of the covalent constructs (i.e. EALYLVCGG; putative P9 underlined) or
may recognize the 12–20 segment in a cross-reactive way. The
recognition of the 12–20 segment by type A T cells in general
was considerably weaker than the 13–21 segment, and the best
example is that of the T cell shown (Fig. 2 a). Moreover, as summarized in Table S2, many of these dual reactive T cells did not
recognize a soluble peptide containing the register 1:12–20,
which is another indication of their weak cross-reactivity.

peptides lacking this residue were presented in register 1.
Without the constraints imposed by the intracellular handling
of insulin by APCs (or by the use of covalent linkages), soluble peptides have the flexibility to be presented in both register 1 and register 2. These findings, summarized in Tables S1
and S2, indicate that register 2 was highly favored under
physiological conditions such as when insulin was processed
and presented by the APCs.
Immunization elicits register 1–reactive type B
T cells in vivo
NOD mice were unresponsive to immunization with insulin
protein but responded to immunization with the B:9–23
peptide, generating T cells that exhibited type B reactivity,
only responding to the peptide but not to insulin (Mohan
et al., 2010). Linking these previous findings to the aforementioned results, the expectation would be that the majority
of B:9–23 T cells elicited in NOD mice would recognize
register 1:12–20. Conversely, immunization with a register
2:13–21 peptide should not elicit a response: mice are highly
tolerant to insulin, and insulin processing by APCs mainly generated register 2:13–21. These expectations were fulfilled.
NOD mice immunized with the B:9–23 or nested register 1 peptide emulsified in CFA elicited a strong ELISPOT
response to the B:9–23 peptide and also to the nested register 1
peptide but not to the nested register 2 peptide or insulin
(Fig. 4 a). The response was inhibited with the addition of
anti–I-Ag7 antibody in the assay. Mice that were immunized
with insulin protein or the nested register 2 peptide did not
elicit a response to any of the peptides (Fig. 4 b).
In our previous study, we showed that type A T cells escaped thymic selection and could be elicited after immunization of the insulin mutant strain B16:A-dKO (Mohan et al.,
2010). These mice have targeted deletions of the native INS1 and INS2
genes but express a mutant insulin
molecule that has a single amino acid
substitution (tyrosine to alanine) at the
16th residue of the B chain (Nakayama
et al., 2005). When B16A-dKO mice
were immunized with the B:9–23 peptide, we detected a response to register 1
similar to that found in NOD mice,
Figure 3. Type A and B T cells recognize
independent registers within the B:9–23
soluble peptide. (a) Response of type A (4F7
and 4E4-62) and type B (8F10 and 2D10)
hybridomas to B:9–23, B:12–20, or B:13–21.
(b) Response to nested B:12–20 with flanking
residues or nested B:13–21 with flanking
residues. (c) Response to nested B:12–21 with
flanking residues or nested B:12–22 with
flanking residues. (d) Response to nested
B:14–22 with flanking residues. Error bars
indicate SEM. Data are representative of three
independent experiments.
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Synthetic peptides confirm register reactivity
of A and B T cells
The findings with covalently bound peptides were extended
using soluble peptides. Although both sets of T cells recognized the B:9–23 peptide, the type A or B T cells did not recognize the B:12–20 or B:13–21 minimal register peptides
when presented by APCs (Fig. 3 a). These findings confirm
that the residues flanking the minimal binding core are required for recognition by insulin-reactive T cells (Levisetti
et al., 2007). To circumvent this issue, synthetic peptides were
designed containing a single register (underlined in the following sequences) nested between artificial flanking residues.
The three amino and carboxyl flanking residues present in
the covalently linked insulin-pMHC molecules were added
to the peptides containing the core registers (Table S2). Akin
to the covalently linked cell lines, type B T cells only recognized the soluble peptide containing the nested register 1,
with flanking residues (TEGVEALYLVCGGGS; Fig. 3 b).
Conversely, a similar peptide containing the nested register 2
(TEGEALYLVCGEGGS) was recognized by type A T cells
but not by type B T cells (Fig. 3 b). Similar to the natural
B:9–23 peptide, peptides containing both registers as their
core, B:12–21 (GTEVEALYLVCGEGGS) and B:12–22
(TEGVEALYLVCGERGGS), were recognized by both type A
and B T cells (Fig. 3 c). A peptide containing register 3,
B:14–22, nested with the same flanks (TEGALYLVCGERGGS)
was not recognized by any of the T cells (Fig. 3 d).
In summary, type A T cells specifically recognized register 2:13–21, whereas type B T cells specifically recognized
register 1:12–20. The P9 glutamic acid (B21) of register 2
had a seminal role in register selection of covalently bound
peptides. All covalently linked peptides containing the B21
glutamic acid were presented on I-Ag7 in register 2, whereas

Br ief Definitive Repor t

Biochemical features of the two main binding segments
The same nested peptides containing the flanking residues
and the core segments (Table S2) were tested in binding
assays to purified I-Ag7 molecules. Peptides containing register
2:13–21 bound better than those containing register 1:12–20,
0.7 µM versus 1.4 µM, respectively. The nested 12–20 register peptide required about double the amount of free peptide
to inhibit the binding of a standard radioactive peptide in
contrast to that of the nested 13–21 register (Table S2; in
seven different experiments with P < 0.03). The peptide
having the 12–21 segment, i.e., both registers, bound at about
the same strength, 0.5 µM, to that of register 2:13–21. Changing the P9 residue to a lysine of register 2:13–21 peptide
greatly decreased the binding capacity and completely inhibited T cell reactivity (Fig. 5 a and Table S2), confirming the
binding register. The effects on binding of lysine substitution
on P9 are less evident with peptides having nonacidic residues. Indeed this was the case with the register 1:12–20 peptide when having a lysine substitution at P9 but nonetheless
completely abrogated T cell recognition (Fig. 5 b and Table
S2). A peptide with the nested register 3:14–22 bound very
weakly at 5.5 µM.
The nested peptide with register 1 had a considerably
faster dissociation rate from I-Ag7, with >50% of the bound
peptide being lost in the first 20 min (Fig. 5 c). In striking
contrast, the nested 13–21 register 2 showed a very slow rate

Figure 4. Immunization of NOD mice gives rise to T cells that recognize register 1 but not register 2 of B:9–23. (a and b) ELISPOT assay of IL-2
secretion by NOD mice immunized with 10 nmol of B:9–23 or register 1:12–20 nested peptide (TEGVEALYLVCGGGS; a) or insulin or register 2:13–21
nested peptide (TEGEALYLVCGEGGS; b) in CFA. (c and d) ELISPOT assay of IL-2 secretion by B16A-dKO mice immunized with 10 nmol of B:9–23 (c) or register 2:13–21 nested peptide (d) in CFA. (a–d) 106 cells from the draining lymph node were restimulated without antigen (No Ag) or with B:9–23 peptide,
insulin (INS), register 1, or register 2 nested peptides (all at a dose of 10 µM) in the presence or absence of a specific blocking antibody to I-Ag7 (G7).
(e and f) Response of insulin-reactive hybridomas B16A-22 (e) and B16A-118 (f) from B16A-dKO mice to B:9–23, nested 12–20 peptide (n-B:12–20), and
nested 13–21 peptide (n-B:13–21). Error bars indicate SEM. Data are representative of two or more independent experiments (n = 3 mice per group).
JEM Vol. 208, No. 12
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but importantly, we detected a response to the insulin protein
and to the nested register 2 peptide (Fig. 4 c), both of which
are absent in NOD mice (Fig. 4 a). Similarly, when we immunized B16A-dKO mice with the nested register 2 peptide, we
detected a specific T cell response to the B:9–23 peptide,
insulin protein, and both register 1 and 2 nested peptides
(Fig. 4 d). The response to register 1:12–20 was unexpected
and required further examination.
Therefore, we tested a panel of type A hybridomas generated from B16A-dKO mice. These hybridomas robustly recognized register 2 and also recognized register 1:12–20 at
similar levels (Fig. 4 e) or to a weaker extent (Fig. 4 f). We
therefore conclude that the dual reactive nature of these
T cells explains the unexpected response to register 1 seen after
immunization of these mice with the nested register 2
peptide (Fig. 4 d).
All together, these results confirm that the majority of
T cells that escape thymic negative selection in NOD mice
are peptide specific and recognize register 1 of the B:9–23
peptide. The presence of register 2–reactive T cells in the
periphery of B16A-dKO mice confirms that the B:13–21
register plays a critical role in mediating negative selection
of insulin T cells. It is currently unclear whether many of
the T cells found in them recognize both registers or
whether they recognize a putative hybrid register of the
register 1 peptide.

2380

binding segment. The environment of the lysosomal compartment, coupled with the weak binding of register 1 to
I-Ag7, leads to the generation of pMHC complexes that are
too unstable to compete and survive their sojourn to the cell
surface in sufficient quantity to stimulate a T cell response.
The presentation of peptides bound in register 1 was
found only in the APCs that normally reside within the islets
of Langerhans (Mohan et al., 2010). Such APCs constitutively
took up insulin granules, many of which, aside from insulin
and C-peptide, also contained peptides derived from the insulin B chain. It stands to reason that the constant exposure
to the secretory granule with preformed insulin B chain
peptides resulted in a significant number of pMHCs bearing
the peptide bound in register 1, a situation akin to the reactivity seen in the culture assays, when APCs are constantly exposed to exogenous synthetic peptides. Whether there are

Figure 5. Binding of register 1:12–20 peptide to I-Ag7 molecules
is unstable and dissociates rapidly compared with binding of register 2:13–21 peptides. (a and b) Response of type A (4F7; a) and type B
(8F10; b) hybridomas to the nested 12–20 peptide (n-B:12–20), nested
12–20 K20 peptide (n-B:12–20 K20), nested 13–21 peptide (n-B:13–21),
and nested 13–21 K21 peptide (n-B:13–21 K21). (c and d) Dissociation
rate of the 12–20 nested peptide (c) and 13–21 nested peptide (d) from
soluble I-Ag7 protein. (e) SDS stability of 12–20 nested peptide I-Ag7 complexes and 13–21 nested peptide I-Ag7 complexes. To denature stable
complexes, samples were boiled before loading as indicated. Molecular
mass is indicated in kilodaltons. (f) H2-DM editing of soluble peptide
I-Ag7 complexes. Bars indicate the percentage of remaining peptide
bound to I-Ag7 after 30 min in the presence of 10-fold molar excess of
H2-DM. Error bars indicate SEM. Data are representative of 3–10
independent experiments.
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of dissociation, and 70% was SDS stable (Fig. 5, d and e).
In accordance with the weak binding of the nested register 1,
most of the bound peptide dissociated when the pMHC
complex was run in SDS-PAGE under nonboiling conditions (Fig. 5 e). Addition of H2-DM to the complex of peptide and I-Ag7 increased the fast rate of dissociation of nested
12–20 to a complete loss after 30 min but had little effect on
nested 13–21 (Fig. 5 f). In sum, the binding features indicate
the register 2:13–21 segment with the B21 glutamic acid at
the P9 MHC anchor residue is much more favorable than
register 1:12–20 in its interaction with I-Ag7.
The present findings extend the previous report of two
major sets of insulin-reactive CD4+ T cells (Mohan et al.,
2010), identify their peptide binding segment to MHC, correlate the recognition in in vivo experiments, and present a
biochemical explanation for their selection. Both sets of
T cells were reactive with the B chain of insulin centered on
a core segment represented by residues 12–21. We show here
that the 12–21 segment contained two adjacent binding registers, giving rise to T cells that recognized one or the other.
More importantly, the register specificity of these T cells corresponded to previously identified subsets of type A and B
insulin–reactive T cells (Mohan et al., 2010), which have
seminal biological differences.
The minor set of insulin-reactive T cells in vivo, type A,
recognizes the register 2:13–21 segment of the B:9–23 peptide. These T cells react with the insulin molecule after its
processing by APCs as well as to the B:9–23 peptide. Such
T cells are under strong selective pressure in the thymus
where insulin is expressed (Mohan et al., 2010). Deletion of
register 2–reactive T cells is not complete, and a limited
number can be found in the periphery and infiltrated islets of
NOD mice (Wegmann et al., 1994; Mohan et al., 2010). In
striking contrast, the majority of insulin T cells found in
NOD mice, the type B T cells, recognize the 12–20 segment
of the B:9–23 peptide. These T cells are not activated by any
source of insulin, explaining their ability to escape thymic
negative selection. Such T cells are selected by the intraislet
APCs, spontaneously infiltrate the islets of prediabetic NOD
mice, and cause diabetes upon transfer (Mohan et al., 2010).
The binding properties of each peptide register plus the
anatomical features of antigen presentation in the islet of
Langerhans explain the presence and features of the two sets
of T cells. The binding characteristics of I-Ag7 typically select
for the presence of peptides bearing one or more acidic residues at the carboxyl end of the peptide (Corper et al., 2000;
Latek et al., 2000; Suri et al., 2002, 2005). A minor set of peptides have small residues bound in the P9 pocket (Stratmann
et al., 2000; Suri et al., 2002, 2005). In the case of the two insulin registers found in the 12–21 segment, register 2 has the
favorable glutamic acid at P9. This register binds better to
I-Ag7, has a longer half-life as a pMHC complex, is more stable in SDS, and is not affected by H2-DM compared with
register 1, which has a less favorable glycine at P9. The contrasting findings of each register are compatible with a scenario in which the processing of insulin selects for the better

Br ief Definitive Repor t

MATERIALS AND METHODS
Mice. NOD and NOD.Cg-Tg(Ins2*Y16A)1Ell Ins1tm1Jja Ins2tm1Jja/GseJ
(B16:A-dKO) mice were obtained from the Jackson Laboratory and maintained in specific pathogen–free conditions. All animal experiments were
approved by the Animal Study Committee of Washington University in
St. Louis.
Expression and isolation of mouse preproinsulin proteins. Mouse
preproinsulin I and II cDNAs were generated from RNA isolated from
NOD pancreatic islet cells. These cDNAs were cloned into the pCR 2.1
TOPO vector (Invitrogen) using the following primer pairs: preproinsulin I
forward primer, 5-ATGGCCCTGTTGGTGCACTTCCTA-3; and reverse primer, 5-TTAGTTGCAGTAGTTCTCCAG-3; and preproinsulin II
forward primer, 5-ATGGCCCTGTGGATGCGCTTCCTG-3; and
reverse primer, 5-CTAGTTGCAGTAGTTCTCCAG-3. The prepro
insulin DNA was subsequently amplified to contain a 5 NcoI site and 3
JEM Vol. 208, No. 12

BamHI site to facilitate cloning into the pET-32c vector (EMD) using the
following primer pairs: NcoI ppINS-1 forward, 5-TCATTACCATGGC
CCTGTTGGTGCACTTCCTA-3; and BamHI ppINS-1 reverse, 5-CTTA
GAGGATCCTTAGTTGCAGTAGTTCTCCAG-3; and NcoI ppINS-2
forward, 5-TCATTACCATGGCCCTGTGGATGCGCTTCCTG-3; and
BamHI ppINS-2 reverse, 5-CTTAGAGGATCCCTAGTTGCAGTAGT
TCTCCAG-3. pET-32c-preproinsulin constructs were transformed into
the origami B (DE3) pLysS Escherichia coli strain (EMD). Bacteria were
grown in a shaking incubator (230 rpm) in LB-ampicillin media at 30°C.
Protein expression was induced when the culture reached an OD600 0.6
with 0.25 mM IPTG (Roche) for 6 h. Bacteria were isolated by centrifugation, and after gentle lysis, preproinsulin proteins were isolated from the cyto
plasmic fraction using Ni-NTA agarose (QIAGEN). Protein was dialyzed
against PBS, pH 7.5, overnight at 4°C. The isolated protein was then concentrated with 10,000 MWCO Centricon columns (Millipore) and treated
with 1 U/mg thrombin (EMD) to separate expression and solubility tags
from the preproinsulin proteins. Proteins were dialyzed twice (24 h each)
against PBS and stored at 4°C.
Cell lines. The T cell hybridomas used in this study were previously described (Mohan et al., 2010). To generate C3.G7 cell lines expressing preproinsulin I and II, DNA was amplified from the pCR 2.1 preproinsulin
constructs using the following primer pairs: NotI ppINS-1 forward, 5-TCAT
TAGCGGCCGCATGGCCCTGTTGGTGC-3; and BamHI ppINS-1
reverse (listed in previous section); and NotI ppINS-2 forward, 5-TCAT
TAGCGGCCGCATGGCCCTGTGGATGCGC-3; and BamHI ppINS-2
reverse (listed in previous section). Amplified DNA was digested and cloned
into the pRetroX-IRES-dsRedExpress vector (Takara Bio Inc.). C3.G7–
preproinsulin I and II stable cell lines were generated by retroviral infection
and sorted multiple times based on dsRed expression for high purity. The
generation of cell lines with covalently linked pMHC molecules is listed in
the next section.
Generation of covalently linked pMHC constructs. The I-Ad  chain was
cloned from NOD splenic cDNA with the following primer pair: NotI G7
forward, 5-TTATGCGGCCGCATGCCGTGCAGCAGAGCTCT-3;
and BamHI G7 reverse, 5-TTCAGGATCCTCATAAAGGCCCTGG
GTGTCT-3 and subsequently cloned into the pQCXIP vector (Takara
Bio Inc.). The I-Ag7  chain with the B:9–23 peptide covalently linked was
isolated from a previously described cell line (Mohan et al., 2010) and cloned
into the pCR 2.1 vector (Invitrogen) with the following primers: NotI G7
forward, 5-TTATGCGGCCGCATGGCTCTGCAGATCCCCAG-3;
and BamHI G7 reverse, 5-CATTGGATCCTCACTGCAGGAGCCCTGCTGG-3. The B:9–23 peptide was removed by XmaI and SpeI restriction digest. Complementary synthetic oligonucleotides of the desired insulin
peptide sequences with restriction enzyme sites (XmaI and SpeI) at the 5
and 3 ends were annealed, digested, and ligated into the I-Ag7  chain construct. The G7 chain with the modified linker (GGSLVPRGSGGGGS)
and covalently bound insulin peptide constructs were cloned in the
pRetroX-IRES-dsRedExpress vector (Takara Bio Inc.) using the NotI and
BamHI restriction sites.
Generation of retrovirus. Phoenix cells (Orbigen) were transfected with
the pQCXIP I-Ad  plasmid and the VSV envelope plasmid with Lipofectamine 2000 (Invitrogen) according to the manufacturer’s protocol. After
48 h, the supernatant was harvested, centrifuged at 3,000 rpm for 10 min to
remove cellular debris, and then applied to M12.C3 cells with 10 µg/ml
polybrene (Sigma-Aldrich). Cells were spinfected at 2,500 rpm for 90 min,
incubated at 37°C overnight, washed, and expanded for another 48 h.
10 µg/ml puromycin (Sigma-Aldrich) was added for 48 h to select for a stable
M12.C3.I-Ad  cell line. This line was subsequently infected with viruses
generated in the same manner containing the G7 peptide constructs. After
infection with the  chain construct, cells were sorted once for expression of
dsRed on a high-speed cell sorter. Expression of I-Ag7 was assessed by flow
cytometry using the AG2.42.7 monoclonal antibody.
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other issues with the islet APCs that allow them to select for
peptides that are bound in register 1 needs to be examined.
An additional consideration is whether there are unique features of the peptides released from  cells that may favor register 1 binding.
We were unable to find any evidence for insulin T cells
recognizing a third register in the B:9–23 segment encompassing 14–22 (Stadinski et al., 2010). T cells against the
14–22 register are unexpected because of the placement of an
unfavored arginine within the P9 pocket, which results in
very weak binding to I-Ag7, even weaker than that of register 1
and 2 segments. The inability to find T cells that recognize
this register indicates that register 3 is unlikely to play an important role in diabetes.
In conclusion, biochemical analyses have given several
explanations for the presentation of peptides from selfproteins. Important are the findings emphasized by us, that
the pMHC complexes presented by APCs in tissues may
differ from those present in the thymic APC system. We
called attention to these in the context of the small protein
HEL where conformational isomers could be distinguished,
which explained the presence of T cells to one set in HEL
transgenic mice (Peterson et al., 1999). In the studies of
spontaneous diabetes in NOD mice, we find selection for
T cells that recognized a segment in which the register
shifted to one poorly presented, if at all, in the thymus.
Previous studies have shown that more than one binding
register can be selected within a relatively short peptide
segment, a phenomenon called register shifting, which
gave rise to nonoverlapping sets of T cells (Scott et al.,
1998; McFarland et al., 1999; Robertson et al., 2000). The
issue of register shifting to explain the escape of autoimmune
T cells has also been discussed in autoimmune encephalomyelitis (Anderton et al., 2002; Seamons et al., 2003;
Bankovich et al., 2004; Goverman, 2009). The conclusion
is that self-reactive T cells can potentially become pathogenic in the target organ where high concentrations of
antigen and/or differences in intracellular processing requirements lead to the presentation of peptides in alternate
conformers or, as shown here, in alternate registers to those
found in the thymus.

Antigen presentation assays. T cell assays were performed in triplicate in
96-well flat-bottom tissue culture plates. T cell hybridomas (5 × 104 per
well) were cultured with 5 × 104 C3.G7 cells in the presence of the indicated
doses of antigen. All peptides used in this study were synthesized in the laboratory using standard protocols. After incubation for 18 h, the culture supernatant from each well was assayed for IL-2 production by a standard bioassay
using the IL-2–dependent cell line CTLL-2.

Biochemical analysis. Biochemical analysis was performed using soluble
I-Ag7 and H2-DM molecules purified from baculoviruses, the same constructs used in previous studies (Pu et al., 2004; Levisetti et al., 2007). Bindings were performed, as detailed previously (Levisetti et al., 2007), by
competition assays of unlabeled peptides to standard 125I-labeled peptide.
The labeled peptide (GKKVATTVHAGYG) was used at concentrations
that bound 25% of input; the concentration of unlabeled peptide that inhibits the binding by 50% was determined. All assays were performed at least
three times. For experiments measuring the rate of dissociation, radioactive
peptide bearing the nested register 1:12–20 or register 2:13–21 sequence was
bound to I-Ag7 overnight at pH 5.5, after which a 1,000-fold excess of cold
peptide was added, and the amounts of labeled peptide were then determined in the isolated complex. In some experiments, H2-DM at a 10-fold
excess molar ratio was added. Peptides used in the bindings assays shown in
Table S2 contained three constant residues at the N terminus (TEG) and
three at the C terminus (GGS) and the core sequence indicated in the table.
For dissociation assays, the peptides were made with an added tyrosine at the
N terminus and changing the tyrosine at B16 to phenylalanine (YEGVEALFLCGGGS and YEGEALFLVGEGGS). The peptides were labeled with 125I
by the chloramine T method.
Online supplemental material. Table S1 lists the sequences of the covalent pMHC molecules and the reactivity of T cells examined. Table S2 lists
the sequences of the synthetic peptides, their binding affinity to I-Ag7, and
the reactivity of T cells examined. Online supplemental material is available
at http://www.jem.org/cgi/content/full/jem.20111502/DC1.
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